The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially supporting the company’s revenue ...

BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in ...

BioMarin is acquiring Amicus Therapeutics for $4.8 billion, merging two rare disease-focused biotechs founded around the turn ...

As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a ...

Backed by a handful of prominent investors including the Gates Foundation, the startup is pursuing an approach it believes ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...

There are long-running TV shows, and then there's Grey's Anatomy. The ABC medical drama is one of the longest-running TV shows of all time and during the run Grey's has had wild medical cases, ...

Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel ...

Past the red carpets and the flashing lights of the paparazzi, some celebrities live in a reality more complicated than what is shown. A number of them live with medical conditions only seen in a tiny ...

BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare diseases.